Emerging Strategies for the Management of Intestinal Failure
|
|
- Angelica Lynch
- 6 years ago
- Views:
Transcription
1 Emerging Strategies for the Management of Intestinal Failure Kelly Tappenden, PhD, RD, FASPEN Human Nutrition Endowed Professor University Distinguished Teacher-Scholar Provost Fellow University of Illinois at Urbana-Champaign \ Editor-in-Chief, Journal of Parenteral and Enteral Nutrition
2 Short Bowel Syndrome Underlying disease Surgical restriction or bypass Short bowel Malabsorption
3 SBS: A Complex and Life-Threatening Disorder A debilitating, complex disorder that may be life-threatening 1,2 Associated with either loss of portions of the intestine or loss of intestinal function 2,3 Typically follows extensive surgical resection of the intestine due to disease, trauma, or congenital defects 2,4 Results in the inability to maintain fluid and nutrient balances through a normal diet 2 Possible causes of resection 3,5 : Vascular catastrophes Complications of bariatric surgery Trauma Malignancy Radiation enteritis Volvulus Strangulated hernias Short bowel fistulas Crohn s disease 1. Hofstetter S, et al. Curr Med Res Opin. 2013;29(5): ; 2. O Keefe SJ, et al. Clin Gastroenterol Hepatol. 2006;4(1):6-10; 3. Nightingale JMD. Intestinal Failure. 2001: ; 4. Buchman AL. Nutrition. 1997;13(10): ; 5. Parrish CR. Practical Gastroenterology. 2005;31:
4 SBS Patients Often Require Parenteral Nutrition After resection, absorptive capacity increases through intestinal adaptation 1,2 Before adequate adaptation is achieved, required nutrients and water must be supplied intravenously 2,3 parenteral nutrition (PN) and/or IV fluids In some patients, adaptation is insufficient to overcome the functional length of bowel that was lost, resulting in permanent PN dependency 3,4 1. Sundaram A, et al. J Clin Gastroenterol. 2002;34(3): ; 2. Buchman AL, et al. Gastroenterology. 2003;124(4): ; 3. Misiakos EP, et al. J Clin Gastroenterol. 2007;41(1):5-18; 4. O Keefe SJ, et al. Clin Gastroenterol Hepatol. 2006;4(1):6-10.
5 Complications of SBS Malabsorption in SBS may lead to complications by causing malnutrition, dehydration, and micronutrient deficiencies 1,2 Many complications of SBS are PS-related. They can be serious and sometimes life-threatening 3 The most relevant malabsorption-related complications The most relevant of SBSPS- related 2,4 complications : of include SBSDiarrhea include 5 : Extreme weight and muscle mass loss Catheter infections Metabolic bone disease Apathy/Depression Hepatic and biliary Reduced disorders wound healing Appearance Reduced quality of of premature life aging Diminished overall health 1. Misiakos EP, et al. J Clin Gastroenterol. 2007;41(1):5-18; 2. Hofstetter S, et al. Curr Med Res Opin. 2013;29(5): ; 3. Buchman AL. Dig Dis Sci. 2001;46(1):1-18; 4. Nightingale JMD. Intestinal Failure. 2001: ; 5. Buchman AL, et al. Gastroenterology. 2003;124(4):
6 Ultimate Treatment Goals 1-5 Reduce Malabsorption- Related Symptoms Enhance Absorption Enable Oral/Enteral Nutrition PS prevents 1,4 : Malnutrition Treatments that Dehydration enhance absorptive Adjunctive capacity may medications reduce 1,4 : improve disease management 1,2 Diarrhea Bacterial overgrowth Reduce or Eliminate PS Minimize PS-Related Complications Improved Disease Management 1. Hofstetter S, et al. Curr Med Res Opin. 2013;29(5): ; 2. Jeppesen PB, et al. Gut. 2011;60(7): ; 3. Parrish CR. Practical Gastroenterology. 2005;31:67-106; 4. Sundaram A, et al. J Clin Gastroenterol. 2002;34(3): ; 5. Vipperla K, et al. Expert Rev Gastroenterol Hepatol. 2011;5(6):
7 Disease Management: Promoting Intestinal Adaptation SBS diet trophic factors Growth hormone (GH), epidermal growth factor, insulinlike growth factors, keratinocyte growth factor, cholecystokinin, gastrin, insulin, and neurotensin Prebiotic/probiotic therapy Glucagon-like peptide-2 (GLP-2)
8 Presence of colon-in-continuity enhances probability of enteral autonomy and survival PN dependency probability (%) Survival probability (%) Messing et al. Gastroenterology 1999;117:
9 Energy absorption increased by functional colon and carbohydrate diet % energy absorbed cho fat Diet cho fat Diet Nordgaard et al., Lancet 1994;343:
10 Colon important in the digestion of carbohydrates and hence in the salvage of calories in patients with SBS Nordgaard et al., Lancet 1994;343:
11 Short Chain Fatty Acids Products of carbohydrate and protein fermentation Acetate, propionate, butyrate comprise 83% of SCFAs Enhance structural and functional adaptation in adult rodent small intestine Unanswered questions: 1. Do SCFA enhance intestinal adaptation in the neonatal intestine? 2. Are the intestinotrophic effects due to the presence of all three SCFA, just the butyrate portion or the total dose of SCFA? 3. How rapidly do SCFA augment intestinal adaptation and are the effects sustained?
12 Neonatal piglet IF preclinical model Similar in nutritional requirements, gastrointestinal physiology and metabolism Clinically relevant shortbowel syndrome and response to TPN Similar body composition to preterm infant Rapid growth and development
13 Experimental Design 48 hours old n = 120 Jugular Catheterization 80% Jejunoileal Resection TPN SCFA 9 mm Bu 60 mm Bu 4h 12h 24h 3d 7d Acute Chronic
14 Butyrate-supplemented PN increases ileal villous length 1000 Villus Length (µm) Control SCFA 9Bu 60Bu Control < SCFA, P <
15 A clinically feasible approach to butyrate delivery Butyrate supplemented PN not currently available SCFA are produced in vivo by bacterial fermentation of malabsorbed carbohydrates Short-chain fructooligosaccharies (scfos), a rapidly fermented prebiotic, may be a clinically efficacious means for delivering butyrate Synbiotic approach necessary? Pre- and probiotics SCFA: butyrate Intestinal adaptation
16 Experimental Design
17 Ileum mucosal weight is increased by the prebiotic treatment, regardless of time txt, p=0.005; day, p=<0.0001; txt x day, p=0.163
18 Prebiotic enhances ileal villous height Ileal villous height (µm) 600 P<0.001 b b ab a Con Pre Pro Treatment Syn
19 Jejunal amino acid/peptide transport increased by prebiotics by Day 7 Δ µa/cm2 (10mM Glutamine) Δ µa/cm2 (10mM GlySar) p<0.001 a b b b b a b p=0.03 ab 0 Con Pre Pro Syn 0 Con Pre Pro Syn
20 Probiotic LGG ineffective at inducing adaptation No added benefit of synbiotic occasionally detrimental Impact on microbiota population potentially resulting in less butyrate production Further work is needed to select the optimal probiotic impact of SBS on infant microbiota Bifidobacteria predominate in healthy infants investigate butyrate producing bacteria for use as probiotics
21 Butyrate-suppl PN plasma [GLP-2] Plasma GLP-2 (pmol/l) Control SCFA 9Bu 60Bu Control < SCFA Treatments, P = 0.007
22 Silencing taste receptors prevent butyrate from increasing GLP-2 Proglucagon mrna abundance (Proglucagon mrna/18s rrna) b a Control b b GPR43 sirna 0 mm Butyrate 7.5 mm Butyrate b b T2R38 sirna p < 0.05
23 What about humans with intestinal failure? Intact Gastrointestinal Tract Short-Bowel Syndrome
24 Role of GLP-2 in Intestinal Adaptation 1 Mucosal hyperplasia in GLP-2- treated murine small intestine 2 Control GLP HIS ALA ASP GLY SER PHE PHE SER SERASP ASP GLU GLU MET MET ASN ASN THR THRILE ILELEU LEUASP ASP ASN ASN LEU LEU ALA ALA ASP THR ILE LYS THR GLN GLNILE ILELEU LEUTRPTRP ASN ASNILE ILEPHE PHE ASP ASP ARG ARG ALA ALA 20 Peptide hormone produced in ileum and proximal colon 1 Induces local release of growth Treatments factors that enhance from enteroendocrine cells, subepithelial myofibroblasts, absorptive capacity and enteric of the neurons of the intestine 2 Drucker DJ, Erlich P, Asa SL, et al. Proc Natl Acad Sci U S intestine may improve A. 1996; 93: disease (1996) National Academy of Sciences, USA. management Evidence indicates GLP-2 plays a role in 1,2 intestinal adaptation 3-5 : levels after resection 3,4 crypt depth and villus height and stimulates intestinal blood 1. Hsieh et al. flow 2,3,4 Gastroenterol 2009;137(3): ; 2. GATTEX (teduglutide [rdna origin]) for injection [package Native insert]. GLP-2 Bedminster, has anj: half-life NPS absorptive capacity 6 Pharmaceuticals; of only 7 minutes, 2012; 3. Drucker limiting et al. itspnas clinical USA. utility. 1996;93: ; 4. Jeppesen et al. Gut. 2000;47: ; 5. Vipperla et al. Exp Rev Gastroenterol Hepatol. 2011;5(6): ; 6. Jeppesen PB et al. Gastroenterol 2001;120: ; 7. Tee et al. Clin Exp Gastroenterol. 2011;4:
25 Teduglutide: A Recombinant GLP-2 AnalogWith Extended Half-life 1, HIS GLY ASP GLY SER PHE SER ASP GLU MET ASN THR ILE LEU ASP ASP THR ILE LYS THR GLN ILE LEU TRP ASN ILE PHE ASP ARG ALA ASN LEU ALA Single amino acid substitution of alanine to glycine at the second position of the N-terminus Mean half-life of 1.3 hours in patients with SBS (vs 7 minutes for endogenous GLP-2) GATTEX is the first and only GLP-2 analog that increases villus height in the intestinal mucosa and enhances the absorptive capacity of the remaining bowel. 1. GATTEX (teduglutide [rdna origin]) for injection [package insert]. Bedminster, NJ: NPS Pharmaceuticals; 2012; 2. Tee CT, et al. Clin Exp Gastroenterol. 2011;4:
26 GLP-2 analog, teduglutide, increases jejunal villus height and crypt depth P = Villus Height (µm) P = P = Crypt Depth (µm) P = P = P = D0 D21 D42 D0 D21 D Crypt Depth (µm) Subjects with jejunostomy Subjects with colon-in-continuity
27 Design of multicenter prospective, randomized, double-blind, placebo-controlled study Placebo (n=43) Subjects 86 PNdependent subjects with intestinal failure Optimize PN Stabilize PN 0-8 wks 4-8 wks Teduglutide 0.05 mg/kg/d (n=43) Intestinal Biopsy 24 wks
28 Primary Endpoint 20 % Reduction in Weekly PS Volume from Baseline 100% Patients, % 80% 60% 40% 63% ** 30% 20% 0% Teduglutide Placebo (n = 43) Please see the Important Safety Information section in this presentation. * Definition of responder. Responder rate (%) was the primary endpoint in STEPS. ** P = vs placebo. 1. GATTEX (teduglutide [rdna origin]) for injection [package insert]. Bedminster, NJ: NPS Pharmaceuticals; 2012; 2. Jeppesen PB, et al. Gastroenterology. 2012;143(6):
29 Teduglutide Reduced Mean Parenteral Support Volume 1,2 Weeks of Treatment Change in PN/IV Volume, L/week (SE) * Teduglutide (n = 43) Placebo (n = 43) -3.0** *** *** *** -2.3 Adapted from Gastroenterology, 143(6), Jeppesen et al, Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure, , 2012, with permission from Elsevier. Please see the Important Safety Information section in this presentation. * P 0.05, ** P 0.01, *** P GATTEX (teduglutide [rdna origin]) for injection [package insert]. Bedminster, NJ: NPS Pharmaceuticals; 2012; 2. Jeppesen PB, et al. Gastroenterology. 2012;143(6):
30 Representative change in small intestinal mucosa following 24 wks of 0.05 teduglutide administration. Baseline End-of-study
31 Teduglutide Reduced Day(s) on Parenteral Support 1,2 100% 80% 1 Day or More Off Parenteral Support per Week Patients, % 60% 40% 20% 54% 23% 0% (21/39) (9/39) Teduglutide Placebo Please see the Important Safety Information section in this presentation. 1. GATTEX (teduglutide [rdna origin]) for injection [package insert]. Bedminster, NJ: NPS Pharmaceuticals; 2012; 2. Jeppesen PB, et al. Gastroenterology. 2012;143(6):
32 Teduglutide Volume and Infusion Frequency PS reductions were sustained in the patients who completed 30 months of continuous treatment with Teduglutide 96% (21/22) of responders in STEPS who enrolled in STEPS2 sustained their response to GATTEX 93% (28/30) of patients achieved a 20% reduction of PS volume Patients who received placebo in STEPS and started Teduglutide in STEPS2 also achieved volume reductions after 24 months of treatment Total Exposure to Teduglutide Efficacy Endpoints Clinical Response ( 20% reduction of PS Volume) Mean reduction in PS volume from baseline (L/week) 30 months (n=30) 24 months* (n=29) 93% (28/30) 55.2% (16/29) 7.55 (65.6%) 3.11 (28.3% )
33 STEPS2 Results: Reduced Days on PS and Complete Weaning 1 The majority of patients who completed 30 months of Teduglutide treatment were able to reduce their days on PS, and a number of them were weaned off PS completely 60% (18/30) patients achieved 3 day reduction of PS per week 10 patients were weaned off PS completely Patients who received placebo in STEPS and started Teduglutide in STEPS2 also achieved reductions in days on PS, and some weaned off PS completely Total Exposure to Teduglutide Efficacy Endpoints Reduction of days per week on PS Weaned off PS completely 30 months (n=30) 24 months* (n=29) 1 d/wk - 70% 2 d/wk - 60% 3 d/wk - 60% 1 d/wk - 70% 2 d/wk - 60% 3 d/wk - 60% 10 2
34 Role of teduglutide and PEN in a neonatal piglet model of IF? Jugular catheterization 80% jejunoileal resection n = 72 TPN PEN (20%) Vehicle Teduglutide (0.1 mg/kg/d) TPN TPN + PEN PEN + 4h, 48h, 7d
35 Teduglutide and PEN small intestine villus height greater than either treatment alone Villus Length Duo Jej Ile PN PEN PN+Drug PEN+Drug TPN- PEN+ Representative mucosal architecture at 7d PEN+ villus length numerically greatest in all segments
36 Take Home Message Strategies to enhance intestinal adaptation, such as prebiotics and GLP-2 therapy, promise to reduce PN in individuals with intestinal failure.
37 Acknowledgements Anne L. Bartholome, Ph.D., R.D. NIDDK R01 DK David M. Albin, Ph.D. NPS Pharma Jennifer Woodard, Ph.D. Jen Barnes, BS Jens J. Holst, M.D., Ph.D.
38 Adverse Reactions* Teduglutide 0.05 mg/kg/day (n = 77) % of Patients Placebo (n = 59) % of Patients Abdominal pain Upper respiratory tract infection Nausea Abdominal distension Vomiting Fluid overload Flatulence Hypersensitivity Appetite disorders Sleep disturbances Cough Skin hemorrhage GI stoma complications** * Adverse reactions in 5% of GATTEX -treated patients in placebo-controlled studies - STEPS and 004 ** Percentages based on 53 subjects with a stoma: Teduglutide (n = 31) and placebo (n = 22).
Parenteral Nutrition. Outline. Potential Biomarkers for Use in Intestinal Adaptation. Jejunum is primary site of digestion and absorption
Outline Potential Biomarkers for Use in Intestinal Adaptation Kelly A. Tappenden, Ph.D., R.D. Professor of Nutrition and GI Physiology 1. Intestinal Adaptation potential regulators 2. Intestinal mucosal
More informationManagement of Short Bowel Syndrome in the Era of Teduglutide. Charlene Compher, PhD, RD University of Pennsylvania
Management of Short Bowel Syndrome in the Era of Teduglutide Charlene Compher, PhD, RD University of Pennsylvania compherc@nursing.upenn.edu Disclosures Research funding for clinical trials by NPS Pharmaceuticals
More informationShort Bowel Syndrome: Medical management
Short Bowel Syndrome: Medical management La Sindrome dell'intestino Corto in età pediatrica Brescia 18 marzo 2011 Jon A.Vanderhoof, M.D. Division of Pediatric GI Harvard Medical School Children s Hospital,
More informationSafety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Syndrome Intestinal Failure
Safety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Syndrome Intestinal Failure O keefe, S.J.D et al, Clinical Gastroenterology and Hepatology Accepted date: 21
More informationteduglutide [rdna origin] (Gattex )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationNutritional Requirements in Intestinal Failure
Nutritional Requirements in Intestinal Failure Christopher Duggan, MD, MPH Center for Nutrition Center for Advanced Intestinal Rehabilitation (CAIR) Division of Gastroenterology, Hepatology and Nutrition
More informationGattex. Gattex (teduglutide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.03 Subject: Gattex Page: 1 of 5 Last Review Date: September 18, 2015 Gattex Description Gattex (teduglutide)
More informationGATTEX (Teduglutide) for Injection REMS Program: Prescriber Education
GATTEX (Teduglutide) for Injection REMS Program: Prescriber Education Shire-NPS Pharmaceuticals, Inc. 300 Shire Way, Lexington, MA 02421 A REMS (Risk Evaluation and Mitigation Strategy) is a program required
More informationGattex. Gattex (teduglutide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.03 Subject: Gattex Page: 1 of 5 Last Review Date: March 16, 2018 Gattex Description Gattex (teduglutide)
More informationDeveloping treatment options for patients with rare gastrointestinal and endocrine disorders and unmet medical need
Developing treatment options for patients with rare gastrointestinal and endocrine disorders and unmet medical need Luke Beshar, senior vice president and chief financial officer BioNJ BioPartnering 2011
More informationGATTEX (teduglutide [rdna origin])
GATTEX (teduglutide [rdna origin]) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationCopyright 2013 Jennifer Lynn Barnes
Copyright 2013 Jennifer Lynn Barnes EFFICACY OF BUTYRATE-PRODUCING THERAPIES FOR USE IN PEDIATRIC INTESTINAL FAILURE BY JENNIFER LYNN BARNES DISSERTATION Submitted in partial fulfillment of the requirements
More informationOn the horizon: trophic peptide growth factors as therapy for neonatal short bowel syndrome.
ISSN: 1472-8222 (Print) 1744-7631 (Online) Journal homepage: http://www.tandfonline.com/loi/iett20 On the horizon: trophic peptide growth factors as therapy for neonatal short bowel syndrome. Patricia
More informationShort Bowel Syndrome and Intestinal Failure: Consensus Definitions and Overview
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:6 10 REVIEWS Short Bowel Syndrome and Intestinal Failure: Consensus Definitions and Overview STEPHEN J. D. O KEEFE,* ALAN L. BUCHMAN, THOMAS M. FISHBEIN,
More informationNutrition Management in GI Diseases
Nutrition Management in GI Diseases Aryono Hendarto MD Nutrition & Metabolic Diseases Division Department of Child Health Cipto Mangunkusumo Hospital University of Indonesia 1 Patient s Care 1. Drugs 2.
More informationOutcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome.
Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome. Carter BA 1, Cohran VC 2, Cole CR 3, Corkins MR 4, Dimmitt RA 5, Duggan C 6, Hill S 7,
More informationThe role of nutrition in optimum gastrointestinal health
The role of nutrition in optimum gastrointestinal health Kelly A. Tappenden, Ph.D., R.D., FASPEN Kraft Foods Human Nutrition Endowed Professor University Distinguished Teacher-Scholar University of Illinois
More informationHealth Benefits of Prebiotic Dietary Fiber
Health Benefits of Prebiotic Dietary Fiber JENNIFER ERICKSON, PhD, RD Objectives Provide some background on dietary fiber To define the term "prebiotic dietary fiber" To discuss potential health effects
More informationESPEN Congress Florence 2008
ESPEN Congress Florence 2008 PN Guidelines presentation PN Guidelines in gastroenterology A. van Gossum (Belgium) ESPEN-Parenteral Guidelines in Gastroenterology André Van Gossum, Eduard Cabre, Xavier
More informationJENNIFER L. BARNES, B.S.
JENNIFER L. BARNES, B.S. Division of Nutritional Sciences 420 Bevier Hall, 905 S. Goodwin Ave. Urbana, IL 61801 barnes2@illinois.edu, 815-685-1554 EDUCATION 2008- present Doctoral Student in Nutritional
More informationDefinition and Types of Intestinal Failure
Definition and Types of Intestinal Failure Jeremy Nightingale Consultant Gastroenterologist St Mark s Hospital Intestinal Failure - Definitions Reduction in functioning gut mass below the minimum amount
More informationAn otherwise healthy 45 year-old man underwent
Carol Rees Parrish, M.S., R.D., Series Editor Short Bowel Syndrome in Adults Part 5 Trophic Agents in the Treatment of Short Bowel Syndrome John K. DiBaise Carol Rees Parrish An important goal when treating
More informationEffect of changing lipid formulation in Parenteral Nutrition in the Newborn Experimental Pathology BSc
Effect of changing lipid formulation in Parenteral Nutrition in the Newborn Experimental Pathology BSc Word count: 6939 0 CONTENTS Abstract...2 Acknowledgements...3 Introduction...4 Materials and Methods...11
More informationSymposium: Glucagon-Like Peptide 2: Function and Clinical Applications
Symposium: Glucagon-Like Peptide 2: Function and Clinical Applications Glucagon-Like Peptide 2: A Key Link between Nutrition and Intestinal Adaptation in Neonates? 1,2 Douglas Burrin,* 3 Xinfu Guan,* Barbara
More informationZorbtive. Zorbtive (somatropin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.24 Subject: Zorbtive Page: 1 of 5 Last Review Date: September 20, 2018 Zorbtive Description Zorbtive
More information1. Describe the relationship of dietary protein and the health of major body systems.
Food Explorations Lab I: The Building Blocks STUDENT LAB INVESTIGATIONS Name: Lab Overview In this investigation, you will be constructing animal and plant proteins using beads to represent the amino acids.
More informationThe top 5 things all doctors should know about nutrition. Dr Peter Mooney Consultant Gastroenterologist Leeds Teaching Hospitals NHS Trust
The top 5 things all doctors should know about nutrition Dr Peter Mooney Consultant Gastroenterologist Leeds Teaching Hospitals NHS Trust ONE NUTRITION IS EVERYONE S PROBLEM 2018 2006 2013 2010 Mortality
More informationIntestinal microbiota and health in piglets
Intestinal microbiota and health in piglets Alfons Jansman Wageningen Livestock Research Nutrition seminar SEGES, April 2018 Introduction What is gut health and what are functions of the gut? Early development
More informationNew Directions in Lactose Intolerance: Moving from Science to Solutions
New Directions in Lactose Intolerance: Moving from Science to Solutions PAPANDREOU DIMITRIOS, PhD, MS., RD. Ass. Professor of Nutrition, University of Nicosia A Barrier to Dairy Consumption Lactose intolerance
More informationAGENDA. Business highlights Significant progress with late stage clinical programs heading towards filing. Britt Meelby Jensen
AGENDA Business highlights Significant progress with late stage clinical programs heading towards filing The Zealand peptide platform World leading expertise delivering differentiated peptide-based drug
More informationNUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #68. Growth Hormone, Glutamine and Glucagon-like Peptide 2 in Short Bowel Syndrome
Carol Rees Parrish, R.D., M.S., Series Editor Growth Hormone, Glutamine and Glucagon-like Peptide 2 in Short Bowel Syndrome Palle Bekker Jeppesen By definition, intestinal failure prevails when oral compensation
More informationBritish Intestinal Failure Alliance (BIFA) position statement: Use of peptide growth factors for adult patients with intestinal failure.
British Intestinal Failure Alliance (BIFA) position statement: Use of peptide growth factors for adult patients with intestinal failure. By Siddhartha Oke, Jeremy Nightingale, Palle Jeppesen and the BIFA
More informationNew Findings in Nutritional Gastroenterology
New Findings in Nutritional Gastroenterology Stephen J O Keefe MBBS, MD, MSc, FRCP Division of Gastroenterology, Department of Medicine University of Pittsburgh Talk Outline Does nutritional support improve
More informationEnteral and parenteral nutrition in GI failure and short bowel syndrome
Enteral and parenteral nutrition in GI failure and short bowel syndrome Alastair Forbes University College London Intestinal failure Inadequate functional intestine to allow health to be maintained by
More informationBringing Synbiotic Interventions in Cancer to Practice: from bench to bedside The UC Davis Foods for Health Institute
Bringing Synbiotic Interventions in Cancer to Practice: from bench to bedside The UC Davis Foods for Health Institute Jennifer T. Smilowitz, PhD Associate Director, Human Studies Research jensm@ucdavis.edu
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominal pain, enteral therapy in acute pancreatitis and, 812 Abscess(es), pancreatic, nutritional support for, 814 815 Acute Physiology and
More informationDietary management. Dr Alison Culkin Lead Intestinal Failure Dietitian St Mark s Hospital RSM December 2017
Dietary management Dr Alison Culkin Lead Intestinal Failure Dietitian St Mark s Hospital RSM December 2017 Overview Effect of resection on absorption Evidence for dietary management in short bowel Practicalities
More informationCopyright 2010 Jennifer Nicole Woodard
Copyright 2010 Jennifer Nicole Woodard BUTYRATE-INDUCED EXPRESSION OF PROGLUCAGON: IMPLICATIONS FOR ENTEROENDOCRINE SIGNALING AND INTESTINAL GROWTH BY JENNIFER NICOLE WOODARD DISSERTATION Submitted in
More informationAmino Acids. Amino Acids. Fundamentals. While their name implies that amino acids are compounds that contain an NH. 3 and CO NH 3
Fundamentals While their name implies that amino acids are compounds that contain an 2 group and a 2 group, these groups are actually present as 3 and 2 respectively. They are classified as α, β, γ, etc..
More informationTotal Parenteral Nutrition and Enteral Nutrition in the Home. Original Policy Date 12:2013
MP 1.02.01 Total Parenteral Nutrition and Enteral Nutrition in the Home Medical Policy Section Durable Medical Equipment Issue Original Policy Date Last Review Status/Date Return to Medical Policy Index
More informationNutritional Management in Enterocutaneous fistula Dr Deepak Govil
Nutritional Management in Enterocutaneous fistula Dr Deepak Govil MS, PhD (GI Surgery) Senior Consultant Surgical Gastroenterology Indraprastha Apollo Hospital New Delhi What is enterocutaneous fistula
More informationObjective: You will be able to explain how the subcomponents of
Objective: You will be able to explain how the subcomponents of nucleic acids determine the properties of that polymer. Do Now: Read the first two paragraphs from enduring understanding 4.A Essential knowledge:
More informationSafety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Intestinal Failure
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2013;11:815 823 Safety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Intestinal Failure STEPHEN J. D. O KEEFE,* PALLE B.
More informationMicrobiome GI Disorders
Microbiome GI Disorders Prof. Ram Dickman Neurogastroenterology Unit Rabin Medical Center Israel 1 Key Points Our gut microbiota Were to find them? Symbiosis or Why do we need them? Dysbiosis or when things
More informationFistuloclysis (distal limb feeding) Dr Alison Culkin Research Dietitian AuSPEN 2015
Fistuloclysis (distal limb feeding) Dr Alison Culkin Research Dietitian AuSPEN 2015 Overview Consider the evidence Describe the practicalities Present some cases Fistuloclysis/distal limb feeding Infusion
More informationWho Needs Parenteral Nutrition? Is Parenteral Nutrition An Appropriate Intervention?
Who Needs Parenteral Nutrition? 1 Is Parenteral Nutrition An Appropriate Intervention? Key questions to ask with initial consultation Can the gastrointestinal (GI) tract be utilized? Can the GI tract be
More informationClinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut
Clinically proven to quickly relieve symptoms of common gastrointestinal disorders GASTROINTESTINAL DISEASE Referred to as gastrointestinal diseases, they are common disorders which affect the esophagus,
More informationSCFA in gut health. Kristin Verbeke. On behalf of the Prebiotic Task Force of ILSI Europe
SCFA in gut health Kristin Verbeke Translational Research in Gastrointestinal Disorders KU Leuven On behalf of the Prebiotic Task Force of ILSI Europe Acetic acid Major anions in the large intestine Propionic
More informationBiological systems interact, and these systems and their interactions possess complex properties. STOP at enduring understanding 4A
Biological systems interact, and these systems and their interactions possess complex properties. STOP at enduring understanding 4A Homework Watch the Bozeman video called, Biological Molecules Objective:
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr REVESTIVE * Teduglutide for injection Powder for solution for injection 5 mg per vial Alimentary tract and metabolism products ATC Code: A16AX08
More informationHome Total Parenteral Nutrition for Adults
Home Total Parenteral Nutrition for Adults Policy Number: Original Effective Date: MM.08.007 05/21/1999 Line(s) of Business: Current Effective Date: PPO, HMO, QUEST Integration 05/27/2016 Section: Home
More informationPARENTERAL NUTRITION THERAPY
UnitedHealthcare Benefits of Texas, Inc. 1. UnitedHealthcare of Oklahoma, Inc. 2. UnitedHealthcare of Oregon, Inc. UnitedHealthcare of Washington, Inc. UnitedHealthcare West BENEFIT INTERPRETATION POLICY
More informationSurgical Nutrition for the Cardiothoracic Patient. Stephanie Kunioki RD, CNSC, LD Memorial Hermann TMC
Surgical Nutrition for the Cardiothoracic Patient Stephanie Kunioki RD, CNSC, LD Memorial Hermann TMC Financial Disclosures NONE Declared PROPER NUTRITION Surgical Effects on Nutrition Intake & Status
More informationDespicable Diarrhea. Darlene G. Kelly, MD, PhD Associate Professor of Medicine Medical Director HPN Program Mayo Clinic Rochester, Minnesota
Despicable Diarrhea Darlene G. Kelly, MD, PhD Associate Professor of Medicine Medical Director HPN Program Mayo Clinic Rochester, Minnesota Conflict of Interest Statement Commercial Interests None Off
More informationMegha Suri. A thesis submitted in conformity with the requirements. for the degree of Master of Science. Institute of Medical Sciences
EXOGENOUS GLUCAGON-LIKE PEPTIDE-2 IN NEONATAL PIGLET MODELS OF SHORT BOWEL SYNDROME: DOES THE INTESTINAL ADAPTIVE RESPONSE VARY WITH REMNANT INTESTINAL ANATOMY? By Megha Suri A thesis submitted in conformity
More informationStrategies for preventing and treating IFALD
Strategies for preventing and treating IFALD Dr Sue Beath The Liver Unit (including small bowel transplantation) sue.beath@nhs.net Birmingham Children s Hospital Intestinal failure associated liver disease
More informationBIOCHEMISTRY REVIEW. Overview of Biomolecules. Chapter 4 Protein Sequence
BIOCHEMISTRY REVIEW Overview of Biomolecules Chapter 4 Protein Sequence 2 3 4 Are You Getting It?? A molecule of hemoglobin is compared with a molecule of lysozyme. Which characteristics do they share?
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acetate, in pediatric surgical patients, 525 526 Acute respiratory distress syndrome (ARDS), immune-modulating nutrition in, 584 585 Aerobic
More informationIntestinal Rehabilitation and Transplantation
Intestinal Rehabilitation and Transplantation Joel Lim, MD Associate Professor of Pediatrics Children s Mercy Hospital University of Missouri in Kansas City Objective: Intestinal Failure/Short Bowel Syndrome
More informationPARENTERAL NUTRITION
PARENTERAL NUTRITION DEFINITION Parenteral nutrition [(PN) or total parenteral nutrition (TPN)] is the intravenous infusion of some or all nutrients for tissue maintenance, metabolic requirements and growth
More informationProteins are sometimes only produced in one cell type or cell compartment (brain has 15,000 expressed proteins, gut has 2,000).
Lecture 2: Principles of Protein Structure: Amino Acids Why study proteins? Proteins underpin every aspect of biological activity and therefore are targets for drug design and medicinal therapy, and in
More informationMalabsorption: etiology, pathogenesis and evaluation
Malabsorption: etiology, pathogenesis and evaluation Peter HR Green NORMAL ABSORPTION Coordination of gastric, small intestinal, pancreatic and biliary function Multiple mechanisms Fat protein carbohydrate
More informationProperties of amino acids in proteins
Properties of amino acids in proteins one of the primary roles of DNA (but far from the only one!!!) is to code for proteins A typical bacterium builds thousands types of proteins, all from ~20 amino acids
More informationCells N5 Homework book
1 Cells N5 Homework book 2 Homework 1 3 4 5 Homework2 Cell Ultrastructure and Membrane 1. Name and give the function of the numbered organelles in the cell below: A E B D C 2. Name 3 structures you might
More informationLong-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome
Citation: (2016) 7, e142; doi:10.1038/ctg.2015.69 & 2016 the American College of Gastroenterology All rights reserved 2155-384X/16 www.nature.com/ctg Long-Term Teduglutide for the Treatment of Patients
More informationCrohn's Disease. What causes Crohn s disease? What are the symptoms?
Crohn's Disease Crohn s disease is an ongoing disorder that causes inflammation of the digestive tract, also referred to as the gastrointestinal (GI) tract. Crohn s disease can affect any area of the GI
More informationהשפעת חיידקים פרוביוטיים
השפעת חיידקים פרוביוטיים החיים בחלל )המעי(... על רון שאול יחידת גסטרו ילדים מרכז רפואי רמב"ם Introduction The intestinal microflora primarily in the large bowel consists mostly on benign bacterial species
More informationPRODUCT INFORMATION. REVESTIVE (teduglutide)
PRODUCT INFORMATION REVESTIVE (teduglutide) NAME OF THE MEDICINE REVESTIVE Active ingredient: teduglutide The active ingredient teduglutide (rdna origin) is a 33 amino acid glucagon-like peptide-2 (GLP-2)
More informationAdvances in intestinal Rehabilitation Susan Hill Gastroenterology Consultant
Advances in intestinal Rehabilitation Susan Hill Gastroenterology Consultant 2 Indication for intravenous nutrition/pn: Intestinal Failure Inability to maintain weight and growth despite adequate enteral
More informationESPEN Congress The Hague 2017
ESPEN Congress The Hague 2017 Meeting nutritional needs of acute care patients Feeding acute pancreatitis patients J. Luttikhold (NL) FEEDING ACUTE PANCREATITIS PATIENTS Joanna Luttikhold, MD PhD Registrar
More informationClassification of amino acids: -
Page 1 of 8 P roteinogenic amino acids, also known as standard, normal or primary amino acids are 20 amino acids that are incorporated in proteins and that are coded in the standard genetic code (subunit
More informationBacteriology. Mycology. Patient: SAMPLE PATIENT DOB: Sex: MRN: Rare. Rare. Positive. Brown. Negative *NG. Negative
Patient: SAMPLE PATIENT DOB: Sex: MRN: 3.2 0.9-26.8 U/g 1.2 0.2-3.3 mg/g 2.2 1.3-8.6 micromol/g 1.1 1.3-23.7 mg/g 1.1 0.2-3.5 mg/g Rare 1.0 0.2-8.8 mg/g Rare 4.4 2.6-32.4 mg/g 64.6 >= 13.6 micromol/g Bacteriology
More informationWhat location in the gastrointestinal (GI) tract has tight, or impermeable, junctions between the epithelial cells?
CASE 32 A 17-year-old boy presents to his primary care physician with complaints of diarrhea for the last 2 days. The patient states that he just returned to the United States after visiting relatives
More informationLevel 2. Non Responsive Celiac Disease KEY POINTS:
Level 2 Non Responsive Celiac Disease KEY POINTS: Celiac Disease (CD) is an autoimmune condition triggered by ingestion of gluten leading to intestinal damage and a variety of clinical manifestations.
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationHOW THE MICROBIOME AFFECTS OUR HEALTH
HOW THE MICROBIOME AFFECTS OUR HEALTH THE INTESTINAL BARRIER AND INTESTINAL PERMEABILITY Intestinal Barrier: a functional body Defense from translocation of dietary antigens, bacteria or bacterial endotoxins
More informationResistant Starch for a Healthy Gut
Resistant Starch for a Healthy Gut Experience Life Resistant Starch for a Healthy Gut Heather Rogers March 2016 Long underappreciated, resistant starch is a friendly carb component that delivers healthy
More informationINTESTINAL MICROBIOTA EXAMPLES OF INDIVIDUAL ANALYSES
EXAMPLES OF INDIVIDUAL ANALYSES INTESTINAL MICROBIOTA Microbiota in the animal or human intestine has evolved together with the host. Consequently, the gastrointestinal tract could be considered a metacommunity,
More informationLower Gastrointestinal Tract KNH 406
Lower Gastrointestinal Tract KNH 406 Lower GI Tract A&P Small Intestine Anatomy Duodenum, jejunum, ileum Maximum surface area for digestion and absorption Specialized enterocytes from stem cells of crypts
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationCopyright 2008 Pearson Education, Inc., publishing as Pearson Benjamin Cummings
Concept 5.4: Proteins have many structures, resulting in a wide range of functions Proteins account for more than 50% of the dry mass of most cells Protein functions include structural support, storage,
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationIntegrative Metabolism: Significance
Integrative Metabolism: Significance Energy Containing Nutrients Carbohydrates Fats Proteins Catabolism Energy Depleted End Products H 2 O NH 3 ADP + Pi NAD + NADP + FAD + Pi NADH+H + NADPH+H + FADH2 Cell
More informationLAB#23: Biochemical Evidence of Evolution Name: Period Date :
LAB#23: Biochemical Evidence of Name: Period Date : Laboratory Experience #23 Bridge Worth 80 Lab Minutes If two organisms have similar portions of DNA (genes), these organisms will probably make similar
More informationEnhancing Bioavailability of Nutrients
Round Table Enhancing Bioavailability of Nutrients Yrjö H. Roos 1 April 2013 ESPCA/São Paulo School of Advanced Science Advances in Molecular Structuring of Food Materials Faculty of Animal Science and
More informationLipids: diverse group of hydrophobic molecules
Lipids: diverse group of hydrophobic molecules Lipids only macromolecules that do not form polymers li3le or no affinity for water hydrophobic consist mostly of hydrocarbons nonpolar covalent bonds fats
More informationThe role of gut microbiome in IBS
The role of gut microbiome in IBS Chung Owyang, MD H. Marvin Pollard Professor of Internal Medicine Professor of Molecular and Integrative Physiology Chief, Division of Gastroenterology Director, Pollard
More informationThe Structure and Function of Large Biological Molecules Part 4: Proteins Chapter 5
Key Concepts: The Structure and Function of Large Biological Molecules Part 4: Proteins Chapter 5 Proteins include a diversity of structures, resulting in a wide range of functions Proteins Enzymatic s
More informationESPEN Congress Brussels Dietary and pharmacological therapy of Intestinal Failure. Bernard MESSING
ESPEN Congress Brussels 2005 Dietary and pharmacological therapy of Intestinal Failure Bernard MESSING Dietary and pharmacological therapy of Intestinal Failure Professeur Bernard MESSING HOPITAL LARIBOISIERE
More informationMethods of Nutrition Support KNH 406
Methods of Nutrition Support KNH 406 Malnutrition 30 50% of hospitalized patients 95% of nursing home patients Resulting in reduced quality of life & increased health care costs May be remedied by providing
More informationSIMPLE BASIC METABOLISM
SIMPLE BASIC METABOLISM When we eat food such as a tuna fish sandwich, the polysaccharides, lipids, and proteins are digested to smaller molecules that are absorbed into the cells of our body. As these
More informationFaecalibacterium prausnitzii
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients PNAS 105(43): 16731-16736, 2008. Speaker: Ming-Cheng Chen Advisor:
More informationMICROBIOM AND OBESITY HEINZ GYAKY 2018 BUDAPEST
MICROBIOM AND OBESITY HEINZ GYAKY 2018 BUDAPEST HUMAN MICROBIOM 10 Billion bacterias are building a 1,5 2 kg heavy human microbiom It is located mainly in the human gut There is a intestinal controlled
More informationOptimizing Protein in a Carbohydrate World
Optimizing Protein in a Carbohydrate World Donald K. Layman, Ph.D. Professor Emeritus Department of Food Science & Human Nutrition University of Illinois at Urbana Champaign The confused consumer 1 Myth:
More informationAmy Bernhard, MS, ACSM-CES Dietetic Intern Morrison Chartwell s Dietetic Internship
Amy Bernhard, MS, ACSM-CES Dietetic Intern Morrison Chartwell s Dietetic Internship 1 Objectives Discuss Lactose Intolerance MNT Lactose Intolerance Low-FODMAP Diet Discussion 2 3 Statistics/Risk Factors
More informationFour Classes of Biological Macromolecules. Biological Macromolecules. Lipids
Biological Macromolecules Much larger than other par4cles found in cells Made up of smaller subunits Found in all cells Great diversity of func4ons Four Classes of Biological Macromolecules Lipids Polysaccharides
More informationSHORT GUT SYNDROME (SGS) : A MANAGEMENT CHALLENGE!
SHORT GUT SYNDROME (SGS) : A MANAGEMENT CHALLENGE! Muhammad Saaiq DEPARTMENT OF SURGERY,PIMS, ISLAMABAD. Surgical Grand Round, Pakistan Institute of Medical Sciences (PIMS), Islamabad. September 23, 2005.
More informationPARENTERAL NUTRITION- ASSOCIATED LIVER DISEASE IN CHILDREN
PARENTERAL NUTRITION- ASSOCIATED LIVER DISEASE IN CHILDREN Praveen Goday MBBS CNSC Associate Professor Pediatric Gastroenterology Medical College of Wisconsin Milwaukee, WI Parenteral Nutrition-Associated
More information